News Asymchem Laboratories (Tianjin) Co., Ltd. OTC Markets

Stocks

ASLT.Y

US04651E1038

Pharmaceuticals

All News

Mentions Relevance

06-11	Asymchem Laboratories Co., Ltd. Approves Final Profit Distribution Plan to Be Implemented (A Shares) for 2025, Payable on June 26, 2026	CI
05-27	AsymBio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates	GL
05-27	AsymBio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates	AQ
05-27	Asymbio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates	CI
05-20	Citigroup's long position in H shares of Asymchem Laboratories (Tianjin) decreases to 4.99% on May 14 from 5.66%, HKEX filing says	RE
05-15	Asymchem Laboratories Co., Ltd. Recommends Final Dividend for the Year Ended 31 December 2025, Payable on 24 July 2026	CI
05-13	Citigroup's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 5.36% on May 7, HKEX says	RE
05-04	JPMorgan Chase's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 7.64% on Apr 28 from 8.18%, HKEX filing shows	RE
04-28	Asymchem Laboratories' Profit Falls 6.8% in Q1; Shares Rise 8%	MT
04-27	Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Asymchem Laboratories (Tianjin) Q1 net profit down 6.8% Y/Y	RE
04-21	Asymchem Laboratories Profit Rises 19% in 2025	MT
04-14	Asymchem Unveils Fully Integrated TIDES Commercial Supply Matrix	CI
04-01	Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$115.43 From HK$114.68, Keeps at Buy	MT
04-01	Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 132.37 Yuan From 131.51 Yuan, Keeps at Buy	MT
03-30	Asymchem Laboratories (Tianjin) 2025 net profit up 19.4% Y/Y	RE
03-30	Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-29	Asymchem Laboratories Co., Ltd. announces Annual dividend, payable on June 26, 2026	CI
03-09	AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities	GL
03-09	AsymBio Completes Dual-Site One-Center Network With Fengxian Commercial Manufacturing Site Operational	CI
02-25	Citigroup's long position in H-shares of Asymchem Laboratories (Tianjin) increases to 11.67% on Feb 19 from 9.34%, HKEX filing shows	RE
12-22	Asymchem Laboratories Cuts Buyback Price Under 2025 Share Scheme; Shares	MT
12-08	Asymbio Commences Commercial Operations At Fengxian Base, Strengthening Global Biopharmaceutical Cdmo Capabilities	CI
25-10-30	Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-30	Asymchem Laboratories (Tianjin) posts qtrly profit attributable RMB182.8 million	RE